The 150 most important questions in cancer research and clinical oncology series:questions 57-66

查看全文 作　　者：Chinese Journal of [1]Cancer

机构地区：[1]Sun Yat-sen University Cancer Center,Guangzhou 510060,Guangdong,P.R.China

出　　处：《Chinese Journal of Cancer》索引2017年第36卷第9期,共7页

摘　　要：Since the beginning of 2017,Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology,which sparkle diverse thoughts,interesting communications,and potential collaborations among researchers all over the world.In this article,10 more questions are presented as followed.Question 57.What are the major stresses that drive the formation,progression,and metastasis of a cancer? Question 58.What is the mechanism responsible for altering an acidic intracellular pH and a basic extracellular pH in normal tissue cells to a basic intracellular pH and an acidic extracellular pH in cancer cells,a fundamental and yet largely ignored phenomenon? Question 59.Where are the tumor-associated plasma microRNAs from in cancer patients? Question 60.Can we identify mechanisms employed by tumor subpopulations to evade standard therapies and seed relapse/metastatic tumors before treatment? Question 61.Why are mutation rates in epidermal growth factor receptor(EGFR) and erb-b2 receptor tyrosine kinase 2(ERBB2) higher in lung cancer from never smokers than that from smokers? Question 62.Does tumor vasculogenic mimicry contribute to the resistance against antiangiogenic therapy in renal cancer? Question 63.What molecular targeted drugs would be effective for non-clear cell renal cell carcinoma(RCC),especially metastatic papillary RCC and chromophobe RCC? Question 64.Can it be more effective by targeting both the vascular endothelial growth factor receptor(VEGFR) and MET signaling pathways in sporadic metastatic papillary renal cell carcinoma(RCC)? Question 65.What are the predictive biomarkers that may be used to identify the renal cell carcinoma(RCC) patients who can benefit from immune checkpoint inhibitor treatment? Question 66.How do we identify predictive molecular biomarkers to stratify clear cell renal cell carcinoma patients for targeted therapies? 关键词：ANTIANGIOGENIC therapy Stress Lung CANCER MicroRNA Renal CANCER Metastasis Vasculogenic MIMICRY EGFR VEGFR ERBB2 MET

相关文献

参考文献（42）
引证文献（3）
耦合文献（19）

参考文献(42)

引证文献(3)

耦合文献(19)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

The 150 most important questions in cancer research and clinical oncology series:questions 57-66

参考文献(42)

引证文献(3)

耦合文献(19)

用户提示